Egetis Therapeutics AB (STU:P0F) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:P0F Egetis Therapeutics AB STU:P0F
45 GF Score
Price €0.53
GF Value €0.48
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:P0F
45GF Score
Egetis Therapeutics AB STU:P0F
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (STU:P0F) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of €0.53 is trading 9.6% above its estimated GF Value™ of €0.48. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for STU:P0F:

  • Interest Received:
  • GF Value™: €0.48 vs. price of €0.53 (9.6% above fair value)
  • GF Score™: 45/100 with 8 warning signs

No single metric tells the full story. See the STU:P0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USAEGTX:Sweden0ABW:UK
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
45GF Score

Get the complete analysis for STU:P0F

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price
€0.48
GF Value